tiprankstipranks
Beijing Airdoc Technology Co. Ltd. Class H (HK:2251)
:2251
Hong Kong Market
Want to see HK:2251 full AI Analyst Report?

Beijing Airdoc Technology Co. Ltd. Class H (2251) AI Stock Analysis

1 Followers

Top Page

HK:2251

Beijing Airdoc Technology Co. Ltd. Class H

(2251)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - Gpt-5.6Sol)
Rating:49Neutral
Price Target:
HK$8.00
▼(-35.69% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily driven by improving fundamentals (re-accelerating revenue growth and much stronger gross margin) and a low-debt balance sheet, but is held back by continued losses and negative/volatile cash flow. Technicals are also weak, with the stock trading below major moving averages and negative MACD, reinforcing near-term caution; valuation is difficult to support due to negative earnings and no stated dividend yield.
Positive Factors
Improving growth and gross margin
The rebound in revenue growth, alongside a substantial gross-margin expansion, indicates improving commercial traction and unit economics. If sustained, stronger gross profitability can provide more resources for product development, market expansion, and the eventual transition toward operating profitability.
Negative Factors
Persistent net losses
Despite better revenue and gross-margin performance, the company has not yet converted its operations into sustainable profit. Continued losses can consume internal resources, constrain investment capacity, and make future performance dependent on successfully improving operating efficiency and commercial scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving growth and gross margin
The rebound in revenue growth, alongside a substantial gross-margin expansion, indicates improving commercial traction and unit economics. If sustained, stronger gross profitability can provide more resources for product development, market expansion, and the eventual transition toward operating profitability.
Read all positive factors

Beijing Airdoc Technology Co. Ltd. Class H (2251) vs. iShares MSCI Hong Kong ETF (EWH)

Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model

Company Description
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical dev...

Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview

Summary
Improving operating trend with revenue growth rebounding to +15.3% in 2025 and gross margin expanding to ~66%, supported by a very low-leverage balance sheet (debt-to-equity ~0.02). However, the company remains loss-making (net margin ~-14%) and cash generation is weak and volatile with negative operating and free cash flow in 2025.
Income Statement
46
Neutral
Balance Sheet
82
Very Positive
Cash Flow
38
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue173.26M156.37M203.96M113.66M115.18M
Gross Profit127.33M86.68M125.13M55.85M70.24M
EBITDA-8.00M-259.70M-113.36M-159.64M-126.73M
Net Income-24.98M-255.46M-132.53M-180.00M-142.63M
Balance Sheet
Total Assets1.31B1.41B1.68B1.74B1.89B
Cash, Cash Equivalents and Short-Term Investments650.73M774.82M1.14B1.41B1.78B
Total Debt26.93M31.88M9.37M8.01M8.20M
Total Liabilities88.07M134.86M127.13M68.59M74.19M
Stockholders Equity1.23B1.27B1.54B1.67B1.82B
Cash Flow
Free Cash Flow-21.09M-167.51M8.02M-392.55M-140.11M
Operating Cash Flow-20.03M-165.43M23.37M-380.44M-112.09M
Investing Cash Flow-49.99M-11.34M-385.14M-154.43M-22.01M
Financing Cash Flow-26.55M-33.31M-18.53M-17.14M1.55B

Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Negative
Last Price12.44
Price Trends
50DMA
9.64
Negative
100DMA
10.51
Negative
200DMA
11.13
Negative
Market Momentum
MACD
-0.39
Positive
RSI
43.82
Neutral
STOCH
38.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2251, the sentiment is Negative. The current price of 12.44 is above the 20-day moving average (MA) of 9.11, above the 50-day MA of 9.64, and above the 200-day MA of 11.13, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 38.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2251.

Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$1.77B8.896.97%9.69%3.85%-1.23%
67
Neutral
HK$1.01B9.745.57%2.44%4.75%
57
Neutral
HK$13.21B23.774.62%160.60%7.92%152.75%
52
Neutral
HK$3.76B45.611.88%1.14%16.87%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
HK$828.11M-10.36-5.98%10.67%57.27%
46
Neutral
HK$1.38B-5.58-14.41%2.56%20.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
8.50
-6.63
-43.82%
HK:1833
Ping An Healthcare and Technology Company
6.13
-16.22
-72.58%
HK:2158
Yidu Tech, Inc.
3.51
-2.63
-42.79%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.50
0.01
0.48%
HK:3309
C-MER Eye Care Holdings Limited
0.82
-1.08
-56.84%
HK:6622
Zhaoke Ophthalmology Ltd.
2.49
-1.51
-37.72%

Beijing Airdoc Technology Co. Ltd. Class H Corporate Events

Beijing Airdoc Swings to Interim Loss as Revenue Declines
Aug 28, 2026
Beijing Airdoc Technology reported unaudited interim revenue of RMB67.3 million for the six months ended 30 June 2026, down from RMB83.7 million a year earlier, while gross profit fell to RMB49.3 million from RMB64.1 million. This indicates weaker...
Beijing Airdoc Flags Interim Loss on Heavy AI and Myopia-Business Investment
Aug 21, 2026
Beijing Airdoc Technology Co., Ltd. has warned investors that it expects to post a net loss of no more than RMB50 million for the first half of 2026, reversing a small profit a year earlier. The company attributes the downturn mainly to heavier sp...
Beijing Airdoc Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 18, 2026
Beijing Airdoc Technology Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to recommend an interim dividend, a decision...
Beijing Airdoc Wins Unanimous Shareholder Backing at 2025 AGM
Jun 26, 2026
Beijing Airdoc Technology Co., Ltd., a Hong Kong-listed Chinese technology company specializing in AI-driven healthcare and diagnostic solutions, continues to build its presence in data-enabled medical services and health management markets. Its g...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2026